Literature DB >> 23334241

Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice.

Yu-qiong Li1, Xiao-bo Li, Shu-jie Guo, Shao-li Chu, Ping-jin Gao, Ding-liang Zhu, Wen-quan Niu, Nan Jia.   

Abstract

AIM: To investigate whether apocynin, a NADPH oxidase inhibitor, produced cardioproteictive effects in Ang II-induced hypertensive mice, and to elucidate the underlying mechanisms.
METHODS: C57BL/6 mice were subcutaneously infused Ang II for 4 weeks to mimic cardiac remodeling and fibrosis. Concomitantly the mice were administered apocynin (100 mg·kg(-1)·d(-1)) or/and the aldosterone receptor blocker eplerenone (200 mg·kg(-1)·d(-1)) via gavage for 4 weeks. Systolic blood pressure (SBP) and heart rate were measured, and transthoracic echocardiography was performed. For in vitro study, cardiac fibroblasts were treated with Ang II (10(-7) mol/L) in the presence of apocynin (10(-5) mol/L) or/and eplerenone (10(-5) mol/L). Immunohistochemistry and Western blotting were used to quantify the expression levels of NADPH oxidase and osteopontin (OPN) proteins in the cells.
RESULTS: Both apocynin and eplerenone significantly decreased SBP, and markedly improved diastolic dysfunction in Ang II-induced hypertensive mice, accompanied with ameliorated oxidative stress and cardiac fibrosis. In the Ang II-treated cardiac fibroblasts, the expression levels of NOX4 and OPN proteins were markedly upregulated. Both Apocynin and eplerenone significantly suppressed the increased expression levels of NOX4 and OPN proteins in the Ang II-treated cells. In all the experiments, apocynin and eplerenone produced comparable effects. Co-administration of the two agents did not produce synergic effects.
CONCLUSION: Apocynin produces cardioproteictive effects comparable to those of eplerenone. The beneficial effects of apocynin on myocardial oxidative stress and cardiac fibrosis might be mediated partly through a pathway involving NADPH oxidase and OPN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334241      PMCID: PMC4002490          DOI: 10.1038/aps.2012.164

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  20 in total

1.  Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injury.

Authors:  C Ceconi; A Cargnoni; E Pasini; E Condorelli; S Curello; R Ferrari
Journal:  Am J Physiol       Date:  1991-04

2.  Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction.

Authors:  Nan Jia; Peixin Dong; Ying Ye; Cheng Qian; Qiuyan Dai
Journal:  Cardiovasc Ther       Date:  2010-10-26       Impact factor: 3.023

Review 3.  New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-19       Impact factor: 29.690

Review 4.  Oxygen, oxidative stress, hypoxia, and heart failure.

Authors:  Frank J Giordano
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

5.  Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat.

Authors:  Yi Zhang; Matthew M K Chan; Miles C Andrews; Trevor A Mori; Kevin D Croft; Katja U S McKenzie; Christopher G Schyvens; Judith A Whitworth
Journal:  Am J Hypertens       Date:  2005-07       Impact factor: 2.689

6.  Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species.

Authors:  Z Xie; D R Pimental; S Lohan; A Vasertriger; C Pligavko; W S Colucci; K Singh
Journal:  J Cell Physiol       Date:  2001-07       Impact factor: 6.384

7.  Myocardial osteopontin expression coincides with the development of heart failure.

Authors:  K Singh; G Sirokman; C Communal; K G Robinson; C H Conrad; W W Brooks; O H Bing; W S Colucci
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

8.  Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice.

Authors:  Agostino Virdis; Mario Fritsch Neves; Farhad Amiri; Rhian M Touyz; Ernesto L Schiffrin
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

9.  Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.

Authors:  Lie Gao; Wei Wang; Yu-Long Li; Harold D Schultz; Dongmei Liu; Kurtis G Cornish; Irving H Zucker
Journal:  Circ Res       Date:  2004-09-30       Impact factor: 17.367

10.  Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.

Authors:  Yutaka Matsui; Nan Jia; Hiroshi Okamoto; Shigeyuki Kon; Hisao Onozuka; Masatoshi Akino; Lizhi Liu; Junko Morimoto; Susan R Rittling; David Denhardt; Akira Kitabatake; Toshimitsu Uede
Journal:  Hypertension       Date:  2004-05-03       Impact factor: 10.190

View more
  17 in total

1.  Nitric oxide generation by the organic nitrate NDBP attenuates oxidative stress and angiotensin II-mediated hypertension.

Authors:  Suênia K P Porpino; Christa Zollbrecht; Maria Peleli; Marcelo F Montenegro; Maria C R Brandão; Petrônio F Athayde-Filho; Maria S França-Silva; Erik Larsson; Jon O Lundberg; Eddie Weitzberg; Erik G Persson; Valdir A Braga; Mattias Carlström
Journal:  Br J Pharmacol       Date:  2016-06-12       Impact factor: 8.739

2.  Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways.

Authors:  Gang Chen; Shi-qi Pan; Cong Shen; Shi-fen Pan; Xiu-min Zhang; Qi-yang He
Journal:  Acta Pharmacol Sin       Date:  2014-03-10       Impact factor: 6.150

3.  Silencing Survivin: a Key Therapeutic Strategy for Cardiac Hypertrophy.

Authors:  Claudia Kusmic; Alessio Vizzoca; Monia Taranta; Lorena Tedeschi; Lisa Gherardini; Gualtiero Pelosi; Ambra Giannetti; Sara Tombelli; Settimio Grimaldi; Francesco Baldini; Claudio Domenici; Maria Giovanna Trivella; Caterina Cinti
Journal:  J Cardiovasc Transl Res       Date:  2021-08-18       Impact factor: 3.216

4.  P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells.

Authors:  Jun Ni; Yang Shen; Zhen Wang; De-cui Shao; Jia Liu; Ya-li Kong; Lan-jun Fu; Li Zhou; Hong Xue; Yu Huang; Wei Zhang; Chen Yu; Li-min Lu
Journal:  Acta Pharmacol Sin       Date:  2014-08-04       Impact factor: 6.150

5.  Regulation of Superoxide by BAP31 through Its Effect on p22phox and Keap1/Nrf2/HO-1 Signaling Pathway in Microglia.

Authors:  Xia Liu; Qing Yuan; Guo-Xun Li; Cong-Cong Jia; Jing-Yu Liu; Yan-Qiu Yang; Xiao-Yu Wang; Yue Hou; Bing Wang
Journal:  Oxid Med Cell Longev       Date:  2021-03-09       Impact factor: 6.543

6.  Sinapic acid prevents hypertension and cardiovascular remodeling in pharmacological model of nitric oxide inhibited rats.

Authors:  Thangarasu Silambarasan; Jeganathan Manivannan; Mani Krishna Priya; Natarajan Suganya; Suvro Chatterjee; Boobalan Raja
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

7.  N-acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure.

Authors:  Beverly Giam; Po-Yin Chu; Sanjaya Kuruppu; A Ian Smith; Duncan Horlock; Helen Kiriazis; Xiao-Jun Du; David M Kaye; Niwanthi W Rajapakse
Journal:  Physiol Rep       Date:  2016-04-13

Review 8.  Role of PI3K/Akt signaling pathway in cardiac fibrosis.

Authors:  Wuming Qin; Linghui Cao; Isaac Yaw Massey
Journal:  Mol Cell Biochem       Date:  2021-07-10       Impact factor: 3.396

9.  C188-9 reduces TGF-β1-induced fibroblast activation and alleviates ISO-induced cardiac fibrosis in mice.

Authors:  Jiao Liu; Yuxuan Jin; Bei Wang; Jinying Zhang; Shengkai Zuo
Journal:  FEBS Open Bio       Date:  2021-06-17       Impact factor: 2.693

10.  Apocynin improving cardiac remodeling in chronic renal failure disease is associated with up-regulation of epoxyeicosatrienoic acids.

Authors:  Kun Zhang; Yu Liu; Xiaoqiang Liu; Jie Chen; Qingqing Cai; Jingfeng Wang; Hui Huang
Journal:  Oncotarget       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.